Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder

Azmeraw T. Amare, Klaus Oliver Schubert, Fasil Tekola‐Ayele, Yi-Hsiang Hsu, Katrin Sangkuhl, Gregory D. Jenkins, Ryan Whaley, Poulami Barman, Anthony Batzler, Russ B. Altman, Volker Arolt, Jürgen Brockmöller, Chia-Hui Chen, Katharina Domschke, Daniel K. Hall‐Flavin, Chen-Jee Hong, Ari Illi, Yuan Ji, Olli Kampman, Toshihiko Kinoshita, Esa Leìnonen, Ying‐Jay Liou, Taisei Mushiroda, Shinpei Nonen, Michelle Skime, Liewei Wang, Masaki Kato, Yu-Li Liu, Verayuth Praphanphoj, Julia Stingl, William V. Bobo, Shih‐Jen Tsai, Michiaki Kubo, Teri E. Klein, Richard M. Weinshilboum, Joanna M. Biernacka, Bernhard T. BauneFrontiers in Psychiatry 2018 · DOI

Abstract

Major Depressive Disorder (MDD) treatment often involves a trial-and-error approach with Selective Serotonin Reuptake Inhibitors (SSRIs). While personality traits are known to correlate with MDD and treatment outcomes, the genetic basis of this link remains under-explored. This study examines whether polygenic scores (PGSs) for the Big Five personality traits can predict SSRI response and remission. Analyzing data from the PGRN-AMPS and ISPC cohorts, we found significant associations for openness, neuroticism, and conscientiousness. Furthermore, cross-trait GWAS meta-analyses identified eight shared genetic loci, highlighting potential molecular pathways connecting personality and antidepressant efficacy.

Introduction

Treating Major Depressive Disorder is a significant clinical challenge, with only about half of patients responding to first-line SSRIs and even fewer achieving full remission. Psychological research has long linked personality traits—specifically high neuroticism and low conscientiousness—to poorer treatment outcomes. However, it has been unclear if these associations are purely behavioral or reflect a shared genetic architecture. This study leverages polygenic scores to investigate the "polygenic load" of personality traits as a predictor for medication response, moving toward a more personalized approach in psychiatry.

Methods

The researchers analyzed genomic data from 1,394 MDD patients across two cohorts: the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS, $n=529$) and the International SSRI Pharmacogenomics Consortium (ISPC, $n=865$).

Two primary analytical methods were used:

  1. Polygenic Scores (PGS): Weighted sums of thousands of genetic variants (SNPs) derived from large-scale external GWAS of personality traits.
  2. Cross-Trait GWAS Meta-Analysis: Identification of specific genetic loci influencing both personality traits and SSRI outcomes using O’Brien’s (OB) and direct Linear Combination (dLC) methods.

Results

The analysis revealed that genetic predispositions for certain personality traits significantly correlate with how patients respond to SSRIs.

Figure 1: Association of personality trait polygenic scores (PGS) with SSRI treatment response and remission across the PGRN-AMPS and ISPC cohorts.

Key Findings by Trait

  • Openness: PGS for openness was a significant predictor of both response and remission. It accounted for approximately 1.5% of the variation in response and 2.8% in remission. The data suggested that openness genetics might influence the tempo of recovery, with different effects observed at 4-week versus 8-week intervals.
  • Neuroticism: High genetic neuroticism was a consistent predictor of lower remission odds. Patients in the highest quartile of neuroticism PGS had roughly 50% lower odds of achieving remission compared to those in the lowest quartile.
  • Conscientiousness: In the PGRN-AMPS cohort, patients with a high polygenic load for conscientiousness had nearly double the odds (1.95x) of a favorable response at 4 weeks.

Shared Molecular Machinery

The cross-trait meta-analysis identified eight specific loci that overlap between personality and drug response:

  • Conscientiousness and Response: One locus near the YEATS4 gene.
  • Neuroticism and Remission: Seven loci near genes including PRAG1, MSRA, XKR6, ELAVL2, PLXNC1, PLEKHM1, and BRUNOL4.

Discussion

These results provide evidence that the link between personality and antidepressant response is rooted in shared molecular pathways. The identification of the YEATS4 locus is particularly noteworthy, as this gene's expression has previously been linked to antidepressant dosage in animal models.

While the variance explained by these genetic scores (1.5–3%) is currently small for standalone clinical diagnostics, they represent a significant step toward precision psychiatry. Future work should focus on larger sample sizes to increase predictive power and the integration of PGS into multi-variable clinical models that include environmental and psychological data.

Conclusion

Polygenic scores for personality traits offer a promising tool for predicting SSRI treatment outcomes in MDD patients. By uncovering the shared genetic architecture between personality and pharmacology, this research paves the way for more tailored and effective treatment strategies in mental health care.

Summary updated

Abstract

Studies reported a strong genetic correlation between the Big Five personality traits and major depressive disorder (MDD). Moreover, personality traits are thought to be associated with response to antidepressants treatment that might partly be mediated by genetic factors. In this study, we examined whether polygenic scores (PGSs) derived from the Big Five personality traits predict treatment response and remission in patients with MDD who were prescribed selective serotonin reuptake inhibitors (SSRIs). In addition, we performed meta-analyses of genome-wide association studies (GWASs) on these traits to identify genetic variants underpinning the cross-trait polygenic association. The PGS analysis was performed using data from two cohorts: the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS, <i>n</i> = 529) and the International SSRI Pharmacogenomics Consortium (ISPC, <i>n</i> = 865). The cross-trait GWAS meta-analyses were conducted by combining GWAS summary statistics on SSRIs treatment outcome and on the personality traits. The results showed that the PGS for openness and neuroticism were associated with SSRIs treatment outcomes at <i>p</i> < 0.05 across P<sub>T</sub> thresholds in both cohorts. A significant association was also found between the PGS for conscientiousness and SSRIs treatment response in the PGRN-AMPS sample. In the cross-trait GWAS meta-analyses, we identified eight loci associated with (a) SSRIs response and conscientiousness near <i>YEATS4</i> gene and (b) SSRI remission and neuroticism eight loci near <i>PRAG1, MSRA, XKR6, ELAVL2, PLXNC1, PLEKHM1</i>, and <i>BRUNOL4</i> genes. An assessment of a polygenic load for personality traits may assist in conjunction with clinical data to predict whether MDD patients might respond favorably to SSRIs.
BibTeX
@inproceedings{amare2018association,
  author = {Azmeraw T. Amare and Klaus Oliver Schubert and Fasil Tekola‐Ayele and Yi-Hsiang Hsu and Katrin Sangkuhl and Gregory D. Jenkins and Ryan Whaley and Poulami Barman and Anthony Batzler and Russ B. Altman and Volker Arolt and Jürgen Brockmöller and Chia-Hui Chen and Katharina Domschke and Daniel K. Hall‐Flavin and Chen-Jee Hong and Ari Illi and Yuan Ji and Olli Kampman and Toshihiko Kinoshita and Esa Leìnonen and Ying‐Jay Liou and Taisei Mushiroda and Shinpei Nonen and Michelle Skime and Liewei Wang and Masaki Kato and Yu-Li Liu and Verayuth Praphanphoj and Julia Stingl and William V. Bobo and Shih‐Jen Tsai and Michiaki Kubo and Teri E. Klein and Richard M. Weinshilboum and Joanna M. Biernacka and Bernhard T. Baune},
  title = {{Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder}},
  booktitle = {Frontiers in Psychiatry},
  year = {2018},
  doi = {10.3389/fpsyt.2018.00065},
}
Figure